China Resources Double-crane Pharmaceutical Co., Ltd. operates in pharmaceuticals, covering new drug development, formulation production, drug sales, active pharmaceutical ingredient manufacturing, and pharmaceutical equipment. The company offers a diverse product portfolio, quality products, and strong distribution capabilities.

China Resources Double-crane Pharmaceutical Co., Ltd. operates in pharmaceuticals, covering new drug development, formulation production, drug sales, active pharmaceutical ingredient manufacturing, and pharmaceutical equipment. The company offers a diverse product portfolio, quality products, and strong distribution capabilities.

China Resources Double-Crane Pharmaceutical reports **CNY 8.07 billion in sales and revenue** for the first nine months of 2026, marking a decline from **CNY 8.40 billion** in the same period of 2025. The company’s earnings reflect a downward trend in financial performance over the year. No additional operational or strategic details are provided in the announcement.

Oct 2026MarketScreenerNews article

China Resources Double-Crane Pharmaceutical’s subsidiary, Beijing Double-Crane Runchuang, secures FDA approval to begin U.S. clinical trials for **DC7001A capsules**, an investigational therapy targeting **systemic lupus erythematosus (SLE)**. The drug’s IND clearance (No. 183387) enables dual-jurisdiction testing, expanding its development pipeline beyond China. DC7001A represents the company’s first FDA-authorized trial for an SLE treatment.

Oct 2026Insight, China's Pharmaceutical IndustryNews article

China Resources Pharmaceutical Group reports softer-than-expected interim earnings while continuing its dividend payout to shareholders. The company maintains financial stability despite reduced profitability in the latest period.

Aug 2026TipRanksNews article

China Resources Double-Crane Pharmaceutical acquires Lier Chemical in a deal valued at **2.37 billion yuan**, advancing its synthetic biology commercialization efforts. The company secured the top bidder position among ten competitors in negotiations for control of Lier Chemical. The transaction, pending finalization, aligns with Double-Crane’s strategic focus on scaling biotech applications.

Jul 2026BigGo FinanceNews article